Food and Drug Administration approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation. More Information. March 22, 2021. |
Monday, March 22, 2021
FDA approves pembrolizumab for esophageal or GEJ carcinoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment